Skip to main content
Fig. 3 | Allergy, Asthma & Clinical Immunology

Fig. 3

From: Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis

Fig. 3

Daily dose of prednisolone from before mepolizumab initiation to the time of the last visit while still on mepolizumab (mean of 3.4 ± 3.0 months after initiation) in EGPA patients in the super-responder group (a) and the responder group (b). Dashes lines show mean dose of prednisolone. Mean values for each patient group were compared by using the Wilcoxon matched-pairs t-test; p < 0.05 was considered statistically significant. †p < 0.01; NS, not significant. Upper brackets at the top show the significance of differences between initiation of mepolizumab treatment versus years 1, 2, 3, and last examination during treatment; lower brackets at the top show the significance of differences between 1 year after initiation of mepolizumab treatment versus years 2, 3, and the last examination during treatment

Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us